Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the efficacy and safety of sugammadex (Bridion) in children with renal failure
2008-008246-20Phase 3Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of Sugammadex in kidney failure and neuromuscular block (NMB) (2 cohorts), sponsored by Radboud University Medical Center. Primary endpoint: Time from start of administration of sugammadex to recovery of the TOF ratio to 0.9. Started Jan 2009; status: terminated.
02
Drugs
Sugammadex
03
Conditions
kidney failureneuromuscular block (NMB)
Beyond the preview
Go deeper on 2008-008246-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008246-20.